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ABSTRACT
Brain metastases constitute a challenge in the management of patients with HER2-
positive breast cancer treated with anti-HER2 systemic therapies. Here we sought to 
define the repertoire of mutations private to or enriched for in HER2-positive brain 
metastases. Massively parallel sequencing targeting all exons of 254 genes frequently 
mutated in breast cancers and/or related to DNA repair was used to characterize the 
spatial and temporal heterogeneity of HER2-positive breast cancers and their brain 
metastases in six patients. Data were analyzed with state-of-the-art bioinformatics 
algorithms and selected mutations were validated with orthogonal methods. Spatial and 
temporal inter-lesion genetic heterogeneity was observed in the HER2-positive brain 
metastases from an index patient subjected to a rapid autopsy. Genetic alterations 
restricted to the brain metastases included mutations in cancer genes FGFR2, PIK3CA 
and ATR, homozygous deletion in CDKN2A and amplification in KRAS. Shifts in clonal 
composition and the acquisition of additional mutations in the progression from primary 
HER2-positive breast cancer to brain metastases following anti-HER2 therapy were 
investigated in additional five patients. Likely pathogenic mutations private to or 
enriched in the brain lesions affected cancer and clinically actionable genes, including 
ATR, BRAF, FGFR2, MAP2K4, PIK3CA, RAF1 and TP53. Changes in clonal composition 
and the acquisition of additional mutations in brain metastases may affect potentially 
actionable genes in HER2-positive breast cancers. Our observations have potential 
clinical implications, given that treatment decisions for patients with brain metastatic 
disease are still mainly based on biomarkers assessed in the primary tumor. 
                             Research Paper
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INTRODUCTION
Brain metastases represent a frequent source of 
morbidity and mortality for breast cancer patients [1]. The 
incidence of brain metastasis in patients with metastatic 
breast cancer varies from 10 to 15% [2] and these rates are 
as high as 50% in patients with the Erb-B2 receptor tyrosine 
kinase 2 (ERBB2 or HER2)-positive breast cancer [3]. 
The central nervous system (CNS) remains a 
sanctuary site for HER2-positive breast cancer [4, 5]. 
Whilst anti-HER2 targeted therapies have resulted in 
better therapeutic control for systemic disease [6–8], 
CNS metastases often occur [9]. Several hypotheses may 
explain this clinical phenomenon, including the poor or 
non-penetration of trastuzumab, a recombinant humanized 
anti-HER2 monoclonal antibody, across the blood-brain 
barrier, better imaging methods for the diagnosis of brain 
metastasis and the increased life expectancy of HER2-
positive breast cancer patients with newer anti-HER2-
targeted therapies [10].
Yet there is a limited understanding of how brain 
metastases evolve from their primary HER2-positive breast 
cancers and how they can be effectively targeted in clinical 
practice. In this study we hypothesized that clinically 
metachronous brain metastasis from HER2-positive breast 
cancers would differ in their repertoire of somatic genetic 
alterations from their respective primary tumor, and that 
potentially targetable driver genetic alterations would be 
enriched in or restricted to the metastases, and could be 
employed as genetic biomarkers to guide the rational use 
of targeted agents. The aims of this study were i) to define 
the repertoire of somatic genetic alterations in primary 
HER2-positive breast cancers and their corresponding 
brain metastases in patients whose lesions metastatic to 
the brain were collected at rapid post-mortem examination 
or surgical excision of the brain metastases, ii) to analyze 
the temporal heterogeneity involved in the progression of 
HER2-positive breast cancers to brain metastasis, and iii) 
to identify potential clinically actionable alterations that 
may allow targeting brain metastasis in HER2-positive 
breast cancer patients. 
RESULTS
The genetic diversity of a brain metastasis from 
a HER2-positive breast cancer patient subjected 
to a rapid post-mortem analysis 
The index patient was a 36-year-old female with an 
ER-negative, HER2-positive invasive ductal carcinoma and 
associated liver metastasis (cT3N3M1) at presentation in 
2012. The patient received first-line therapy with the anti-
HER2 trastuzumab plus paclitaxel; following successive 
visceral and brain progression (7.5 months after diagnosis), 
the patient received whole brain radiotherapy and three 
additional lines of anti-HER2 therapies combined with 
cytotoxic and/or targeted agents i) capecitabine, trastuzumab, 
BKM120; ii) lapatinib, capecitabine, iii) vinorelbine, 
trastuzumab. The patient expired 18.6 months after the 
initial diagnosis and was subjected to a rapid post-mortem 
examination (Figure 1A and 1B and Table 1). In the final 
radiological assessment ~21 days before death, the patient 
had no measurable systemic extra-cranial visceral metastases 
(the liver metastasis was in clinical complete remission) 
except for the supra and infratentorial anatomically distinct 
brain metastases that were longitudinally followed up from 
the diagnosis of the CNS infiltration to the post-mortem 
analysis (Figure 1A and 1B).
The primary tumor and three spatially separated 
brain metastases were subjected to high-depth targeted 
sequencing of 254 genes frequently mutated in breast 
cancer and/or related to DNA repair (Supplementary 
Table 1) to 238× in the primary tumor, a median depth 
of 1,267× (range: 1,056×–1,503×) in the metastases and 
to 1,109× in the matched normal sample (Supplementary 
Table 2). All mutations found by targeted sequencing 
where genomic DNA was available were subjected to 
orthogonal validation using amplicon resequencing 
(Supplementary Tables 3 and 4). 
We sought to define whether intra-tumor genetic 
heterogeneity would be present between the primary 
breast cancer and the brain metastatic deposits, and 
whether the progression from HER2-positive primary 
breast cancer metastatic to the brain following anti-
HER2 therapy was associated with shifts in clonal 
composition. Overall, the primary breast cancer and the 
three synchronous and spatially distinct brain metastatic 
lesions, in addition to displaying a clonal ERBB2 (HER2) 
gene amplification, harbored 27 somatic mutations 
(Figure 1C). The likely pathogenic TP53 X261_splice 
mutation was clonal (as defined by ABSOLUTE [11]) 
and ubiquitously present in the primary tumor and in 
the three brain metastatic deposits. The PAXIP1 L537F 
mutation was subclonal in the primary tumor and 
expanded to become clonal in the brain metastases. 
Among the 27 somatic mutations, 24 were restricted 
to the brain metastases, of which 4 affected cancer-
related genes (i.e., FGFR2, MAP2K4, ATR and PIK3CA) 
(Figure 1C) [12–16]. The likely pathogenic FGFR2 
D759H missense mutation was clonal in the three 
metastatic deposits found in the patient. Most of the 
somatic mutations identified were private to one of the 
metastatic deposits and the likely pathogenic hotspot 
PIK3CA K111T mutation, a recurrently mutated residue 
in breast cancer [16], was private to and clonal in the 
brain metastasis #2 (BM2). 
Analysis of the CNAs demonstrated that ERBB2 
amplification was present both in the primary tumor 
and all brain metastases; reinforcing its role as an early 
‘truncal’ event (Figure 1D). By contrast, we observed 
a homozygous deletion on chromosome 9p21.3 in the 
three brain metastases but not in the primary breast 
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cancer. This locus encompasses the CDKN2A (p16) 
gene, an important tumor suppressor gene with a central 
role in cell cycle regulation. Furthermore, the brain 
metastasis #1 (BM1) showed a private (i.e., not present 
in the primary tumor or in the other synchronous brain 
metastases) amplification on chromosome 12p12.1, 
encompassing the KRAS gene. 
A phylogenetic analysis of the somatic mutations 
and CNAs of the index patient suggested that the brain 
metastatic lesions diverged from the primary tumor and 
acquired additional likely pathogenic mutations in the 
cancer genes FGFR2, PIK3CA and ATR, homozygous 
deletion in CDKN2A and amplification in KRAS (Figure 
1E). This led us to expand our cohort to investigate 
temporal heterogeneity in pairs of HER2-positive primary 
breast tumor and brain metastases.  
Characterization of somatic genetic alterations 
of primary breast cancers and their 
metachronous brain metastases in five additional 
patients
Sequencing of an additional five primary HER2-
positive breast cancers and corresponding six brain 
metastases was performed to median depths of 447× 
(range: 84×–645×), 392× (range: 139×–1,148×) and 
467× (range: 196×–1,790×) in the primary tumors, brain 
metastases and matched normal counterparts, respectively 
(Table 1, Supplementary Table 2). 
Across the five cases, the primary tumors and 
the metastases harbored a median of 3 (range: 1–24) 
and 10 (range: 1–38) somatic mutations, respectively 
(Supplementary Table 4), with a higher number of somatic 
mutations in the brain metastases than the corresponding 
primary tumors (P = 0.02, paired Mann-Whitney U-test, 
Figures 1C and 2). Overall, 111 somatic mutations 
targeting 73 genes were detected (median 16.5 per case, 
range 1–49), including 18 likely pathogenic mutations 
in 11 cancer genes (AKAP9, ATM, ATR, BRAF, CDH1, 
ERBB2, FGFR2, MLH1, PIK3CA, RAF1 and TP53, 
Figures 1C and 2). A pairwise comparison revealed that a 
median of 17% (range: 0%–100%) of the mutations were 
shared by the primary tumors and corresponding brain 
metastases, while a median of 15% (range: 0%–22%) 
and 60% (range: 0%–88%) were restricted to the primary 
tumors and metastases, respectively (Figures 1C and 2). 
Hotspot mutations [17] present in both the primary tumor 
and brain metastasis were identified in Cases 1 (PIK3CA 
E542K) and 12 (TP53 H214R and PIK3CA H1047R, 
Figure 2). Most CNAs were present in both the primary 
tumor and the brain metastases (Supplementary Figure 2), 
consistent with the notion that CNAs are early events in 
breast cancer tumorigenesis, likely constituting punctuated 
evolutionary bursts [18]. Importantly, ERBB2 amplification 
was present and inferred by FACETS [19] to be clonal in 
all primary tumors and their respective brain metastases, 
therefore likely represented a ‘truncal’ genetic event. 
Further focal amplifications present in both the primary 
tumors and their respective brain metastases affected 
19q13.33 (encompassing NR1H2 and POLD1, Case 2) and 
12q13.2–15 (ERBB3, CDK4 and MDM2, Case 6).
Of particular interest are the 61 genes affected by 
mutations selected for in the brain metastases, including 
those mutations private to, enriched in, or associated with 
secondary LOH event in the brain metastasis. These genes 
included 54 genes affected by 73 mutations that were 
private to the brain metastases, 31 of which that were 
clonal in at least one of the brain metastases analyzed, 
including two hotspot mutations in TP53 (Case 1, Y236C 
and Case 2, R248W), as well as seven likely pathogenic 
mutations in ATR, FGFR2, PIK3CA, RAF1, TP53, and 
WDFY3 (Figures 1C and 2). We further identified 11 genes 
affected by 12 mutations that were enriched in the brain 
metastasis, including pathogenic hotspot mutations in 
PIK3CA (Case 12, H1047R) and TP53 (Case 12, H214R). 
Two genes (TOP2A and TP53) were affected by three 
shared mutations that were associated with a secondary 
LOH event in the metastases but not in the primary 
tumor in Case 14, including a TP53 Q331* truncating 
mutation. Collectively, the mutations private to, enriched 
in, or associated with a secondary LOH event in the brain 
metastasis affected 61 genes. Additionally, the index 
case harbored copy number alterations restricted to the 
brain metastases (KRAS amplification in brain metastasis 
#1, CDKN2A homozygous deletion in all three brain 
metastases) (Figure 1D).
Mutational processes that shape the human 
genome can be deduced from the pattern of somatic 
mutations detected in cancer cells [20]. For Case 14, the 
high mutation burden allowed us to identify signatures 
associated with increased APOBEC cytidine deaminase 
activity (2 and 13  [20]) as the predominant signatures 
among the mutations shared between the primary tumor 
and the brain metastasis and among the mutations private 
to the metastasis (Supplementary Figure 1). Mutations 
private to the primary breast cancer were associated 
with signature 2 (APOBEC) and 3 (homologous 
recombination deficiency), although the number of 
mutations private to the primary was small and the 
mutations were not associated with an increased burden 
of small insertions and deletions. In the remaining cases, 
this analysis was not possible, as the tumors harbored 
< 20 somatic mutations.
Taken together, these results suggest that primary 
HER2-positive breast cancers and their respective 
metachronous brain metastases displayed important 
genetic differences that affected cancer genes. Of note, 
four of the six cases harbored TP53 likely pathogenic 
mutations (three hotspot mutations and one truncating 
mutation) that were private to or enriched in the brain 
lesions, all of which were associated with LOH of the 
wild-type allele in the metastatic deposit.
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Tumor progression from the breast cancer to the 
brain site is underpinned by temporal genetic 
heterogeneity
The tissue samples in Case 12 were longitudinally 
collected, thus we sought to define whether shifts in clonal 
composition would take place in the progression from the 
primary tumor to the brain metastases in this HER2-positive 
breast cancer following anti-HER2 therapy (Table 1). 
Case 12 was a 40-year-old woman, diagnosed in 
2005 with locally advanced ER-positive/HER2-positive 
breast cancer (Figure 3A). The patient was treated with 
neoadjuvant therapy (anthracycline and taxane-based 
therapy), mastectomy and adjuvant chemotherapy, followed 
by adjuvant radiotherapy and trastuzumab plus tamoxifen. 
The patient developed a single cerebellum metastasis (brain 
metastasis # 1) 18.1 months from after the diagnosis of 
primary breast cancer. This patient had a complete surgical 
excision of the brain metastasis in 2007 (ER- and PR-
negative, HER2 not tested during clinical care), followed by 
radiotherapy. The patient recurred after 17 months and was 
treated with radiosurgery and anti-HER2 and taxane-based 
therapies achieving partial response with an incomplete 
surgical excision in 2009. The residual lesion increased in 
size five months after surgery. The patient started treatment 
with lapatinib and capecitabine. The brain metastasis # 2 was 
surgically treated in 2010 after six months on chemotherapy 
(ER- and PR-negative, HER2-positive) (Supplementary 
Figure 3). After a new CNS progression, the patient was 
treated with anti-HER2 systemic therapy, and expired in 2011. 
The analysis of the sequential brain metastases 
revealed that two likely pathogenic hotspot mutations TP53 
H214R and PIK3CA H1047R were enriched in the brain 
metastasis as compared to the primary tumor (Figure 2 and 
Figure 3B). In particular, the enrichment of the TP53 H214R 
mutation coupled with LOH of the wild-type allele in the 
brain metastases was confirmed by p53 IHC demonstrating 
the evident enrichment of p53 expression in more than 80% 
of the cells in brain metastasis #2 compared to the primary 
breast cancer (Figure 3B). We identified six mutations that 
were present in both brain metastases but not in the primary 
tumor, including three likely pathogenic clonal mutations 
affecting RAF1 and WDFY3. Additionally, private mutations 
were identified in each of the two brain metastases, including 
a likely pathogenic mutation in ZNF703 in brain metastasis 
#1 and likely pathogenic mutations affecting MAP2K6, 
PRKCA, CACNA1A and CHD6 in brain metastasis #2 
(Figure 3B). These results suggest that progression from 
primary tumor to brain metastasis after several lines of 
chemo and targeted therapy was associated with clonal shifts 
and the acquisition of additional mutations. 
Clinical ‘actionability’ of genetic alterations 
present in HER2-positive brain metastases 
Given that the progression of the breast cancers 
to the brain metastasis (median 22.75 months, range 
7.5–39, Table 1) showed evidence of spatial and temporal 
genetic heterogeneity, we interrogated the 402-gene 
list derived from DGIdb [21, 22] and the 373-variant 
list from OncoKB [23] (Supplementary Tables 5 and 6) 
to determine the actionability of the likely pathogenic 
mutations that were private to, enriched in or associated 
with secondary LOH events in the brain lesions, and the 
genes affected by CNAs private to the brain lesions.
Among the 54 genes affected by 73 mutations, as 
well as KRAS and CDKN2A (affected by amplification and 
homozygous deletion, respectively, restricted to the brain 
metastases in the Index case) private to, enriched in or 
associated with secondary LOH events in the brain lesions, 
11 genes were considered actionable based on DGIdb 
(Table 2). In particular, both mutations in PIK3CA and all 
four mutations in TP53 affected hotspot residues (Table 2). 
Considering the actionability of specific alterations based 
on OncoKB, CDKN2A homozygous deletion (level 4 
evidence), and both oncogenic mutations in PIK3CA were 
considered clinically actionable (level 3A evidence for 
breast cancer, Table 2). Taken together, our results suggest 
that a small but important subset of genetic alterations 
private to, enriched in or associated with secondary LOH 
events in the brain lesions may be clinically targetable.
DISCUSSION
The development of brain metastases is a major 
limitation to life expectancy and contributes to the poor 
outcomes to patients with HER2-positive breast cancer. 
Patients with HER2-positive breast cancer have a higher 
risk of developing brain metastases [24]. This may be a 
direct result of the inability for trastuzumab to efficiently 
overcome the blood-brain barrier. Although traditional 
modes of administration of trastuzumab improve the 
outcome of HER2-positive breast cancer patients with 
brain metastases [25, 26], intrathecal administration 
might represent an alternative to overcome blood-brain 
barrier [27]. Studies comparing the genetic alterations in 
paired primary breast cancer and distant metastases have 
been performed [28–31]. However, the unique biology 
and challenging clinical course of HER2-positive breast 
cancers metastasized to the brain suggest that they warrant 
further and specific characterization to identify candidate 
molecular targets. 
To define the genetic alterations associated with 
the development and progression of brain metastasis 
from patients with HER2-positive breast cancers, we 
assessed the somatic genetic alterations in the primary 
breast cancer and in up to three brain metastatic deposits. 
Recent studies of paired primary breast cancer and 
distant metastases (including but not limited to the 
brain) revealed that mutations in TP53, PTEN, KRAS and 
SMAD4 were frequently restricted to the metastases [28–
31]. In addition, ESR1, PALB2, FSIP2, AGRN, FRAS1, 
IGFN1, EDC4, OSBPL3 were found to be significantly 
more frequent in prospectively accrued metastatic 
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breast cancers than in primary breast cancers from The 
Cancer Genome Atlas (TCGA) [32]. These observations, 
however, largely stem from the analysis of ER-positive/
HER2-negative metastatic breast cancers [32]. In our 
series of six HER2-positive breast cancers with brain 
metastasis, four cases harbored TP53 likely pathogenic 
mutations private to or enriched in the brain metastases. 
Indeed, our results here, as well as those from previous 
studies [33–36], suggest that breast cancers may 
undergo clonal shifts and acquire additional somatic 
genetic alterations in the progression from primary to 
metachronous brain metastasis after systemic therapy. 
HER2 amplification as a truncal alteration is likely to be 
true for the majority of HER2-positive breast cancers. A 
small subset of HER2-positive breast cancers, however, 
exhibit non-uniform patterns of HER2 overexpression 
and HER2 gene amplification [37]. In these cases, it 
is uncertain whether HER2 amplification is an early 
alteration that is lost during tumor development or is 
gained later in the evolution of the tumor. In fact, loss 
of HER2-positive status can occur in metastatic tumors 
from patients with primary HER2-positive breast cancer 
[38], probably due to eradication of the HER2-positive 
major clone and secondary expansion of a minor clone 
lacking HER2 gene amplification. An important clinical 
implication of this observation is that sequencing of 
primary biopsies alone may miss a substantial number 
of opportunities for targeted therapy in this cohort of 
patients [34]. 
Currently, there are increasing efforts to match 
potential clinically actionable genetic alterations with 
targeted therapy to accomplish the goals of precision 
medicine in the context of brain metastases [34]. A recent 
sequencing analysis of a series of 86 pairs of primary 
solid tumors and matched brain metastasis, including 21 
cases with breast cancer primary, demonstrated that in 
53% of cases, at least one clinically actionable genetic 
alteration was restricted to the brain metastasis, in 
particular alterations that may confer sensitivity to PI3K/
AKT/mTOR, CDK, HER2/EGFR and MAPK pathway 
inhibitors [34]. In the six patients analyzed in this study, 
we found alterations that may confer sensitivity to PI3K/
AKT/mTOR, CDK and MAPK pathway inhibitors in two 
(Index case and Case 12, PIK3CA K111T and H1047R, 
respectively), one (Index Case, CDKN2A homozygous 
deletion), and two cases (Case 14, BRAF E703D and Case 
12, RAF1 D19Y and D23H), respectively. Additionally, 
we identified likely pathogenic mutations private to 
or enriched in the brain metastases that are potentially 
targetable with PARP inhibitors and/or drugs that target 
replication stress in two cases (likely pathogenic mutations 
in ATR in Index case and Case 14), or with multi-target 
Table 1: Clinico-pathologic characteristics and outcome of the six patients included in the study
Patient 
ID
Breast cancer 
subtype
Histologic 
subtype
Age at 
diagnosis 
(years)
Anti-HER2 therapy administered between 
the diagnosis of the primary breast cancer 
and the collection of the brain metastases
Time to brain 
metastasis 
diagnosis 
(months)
Extra-cranial 
disease
Overall 
survival 
(months)
Index ER-negative/HER2-positive IDC 36 Trastuzumab plus taxanes 7.5
No extra-cranial 
disease at the 
last clinical 
assessment before 
death
18.6
Case 1 ER-negative/HER2-positive ILC 44
Neo (adjuvant): anthracycline and taxanes-
based plus trastuzumab 26.3
Bone metastasis 
in lumbar 
vertebrae (L4) 
synchronous to 
brain metastasis
67
Case 2 ER-positive/HER2-positive IDC 40
Adjuvant: anthracycline and taxanes-
based plus endocrine therapy. No adjuvant 
trastuzumab due to low ventricular ejection 
fraction
26.1
Axillary lymph 
node and 
leptomeningeal 
carcinomatosis a 
posteriori to the 
diagnosis of brain 
metastasis
58.3
Case 6 ER-positive/HER2-positive IDC 30
Adjuvant: anthracycline and taxanes-based 
plus trastuzumab and endocrine therapy. 
Metastatic setting: Capecitabine plus 
vinorelbine
39
Bone lesion 
resected, then 
irradiated
52
Case 12 ER-positive/HER2-positive IDC 40
Neo (adjuvant):  anthracycline and taxanes-
based plus adjuvant chemotherapy followed 
by trastuzumab and endocrine therapy
18.1* No 62.6
Case 14 ER-negative/HER2-positive IDC 52
Neoadjuvant: anthracycline and taxanes-
based plus trastuzumab 19.5 No 27.6
ER, estrogen receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
*Time to the first brain metastasis.
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angiokinase inhibitors in one case (FGFR2 D759H in 
Index case). Taken together, four of six cases (67%) were 
found to harbor at least one likely pathogenic genetic 
alteration private to or enriched in the brain metastases 
that may be clinically targetable (Table 2). Of note, 
most of these genetic alterations can be targeted with 
small molecule inhibitors that can potentially cross the 
blood-brain barrier. Moreover, the majority of brain 
macrometastases (> 1 mm diameter) show variable 
extent of disturbance of the blood-brain barrier [39, 40], 
potentially allowing the small molecule inhibitors and 
other agents to reach the brain metastases. Our results 
suggest that different subtypes of HER2-positive breast 
cancer patients may be defined based on their repertoire 
of genetic alterations in the brain metastasis and potential 
targeted drugs directed against these alterations tested in 
the context of clinical trials.
In Case 14 (ER-negative/HER2-positive) we 
identified an enrichment in the signatures related to 
APOBEC-mediated mutagenesis (signatures 2 and 13) 
[20], which was previously described as enriched in 
metastatic tumors compared to primary tumors, in the 
context of HER2-negative breast cancers [32]. Our 
observation provides evidence to suggest that APOBEC-
Table 2: Potentially targetable genes and systemic therapies for genes harboring likely pathogenic 
mutations that were private to, enriched in or associated with secondary LOH events in the brain 
lesions, and the genes affected by CNAs private to the brain lesions
Actionable 
genes 
(DGIdb)
Private to the brain 
metastases
Hotspot 
mutation
Actionable 
alteration 
(OncoKB)
Selected systemic therapies
ATR
Index case (C2150W)* - - Nirapanib, BMN673, Olaparib, Rucaparib, 
VeliparibCase 14 (E1878Q)* - -
BRAF Case 14 (E703D)* - -
Vemurafenib, Dabrafenib, Dabrafenib + 
Trametinib, Vemurafenib + Cobimetinib, 
Trametinib (Level 1)
CDKN2A Index case (homozygous deletion)* - Yes
Palbociclib + Letrozole
 (Level 4)
FGFR2 Index case (D759H)* - - JNJ-42756493, Debio1347 (Level 3A)
KRAS Index case (amplification)* -
#
Docetaxel + Trametinib, Abemaciclib, Erlotinib + 
Binimetinib, Selumetinib, Binimetinib, Ribociclib 
+ Trametinib, Palbociclib, Ribociclib, Palbociclib 
+ PD0325901, Trametinib 
Binimetinib + Alpelisib, Cobimetinib + GDC-0994 
(Level 4)
MLH1 Case 14 (R100Q)* - - -
PIK3CA
Case 12 (H1047R)** Yes Yes Buparlisib, Serabelisib, Alpelisib + Fulvestrant, 
Copanlisib, Fulvestrant + Taselisib, GDC-0077, 
Alpelisib, Buparlisib + Fulvestrant, Taselisib
 (Level 3A)
Index case (K111T)** Yes Yes
RAF1 Case 12 (D19Y and D23H)* - - Sorafenib (Level 4)
TOP2A Case 14 (D524N and D526N)*** - -
Doxorrubicin, Teniposide, Valrubicin, Idarubicin, 
etoposide
TP53
Case 1 (Y236C)* Yes -
-
Case 2 (R248W)* Yes -
Case 12 (H214R)** Yes -
Case 14 (Q331*)*** Yes -
ZNF703 Case 12 (S389W)* - - -
  *Private to the brain metastasis
 **Enriched in the brain metastasis
***Associated with LOH in the brain metastasis
  #as per OncoKB, oncogenic mutations in KRAS are actionable (level 4 evidence).
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mediated mutagenesis may contribute to the genetic 
heterogeneity between the primary tumor and the brain 
metastasis in HER2-positive breast cancer. Our findings 
suggest that further studies investigating shifts in 
mutational signatures in the progression of breast cancers 
from patients receiving specific modalities of systemic 
therapies are warranted.
Our study has several limitations. First, due to 
the challenges posed in tissue procurement of brain 
metastasis, our cohort size was small. Our patient 
population comprises patients with HER2-positive breast 
cancers that developed brain metastasis as a unique or 
main metastatic site and underwent brain metastasis 
excision or rapid autopsy. Despite the small sample size, 
Figure 1: The somatic genetic alterations in the primary breast tumor and the three synchronous, spatially distinct 
brain metastatic lesions of the index case. (A) Longitudinal representation of computer tomography scans, showing coronal sections 
in T1W1 and the presence of 3 main lesions: BM1, left frontal lobe, BM2, basilar ganglion, BM3, right occipital lobe during the timepoint 
1 (06.05.2013), timepoint 2 (12.12.2013) and timepoint 3 (17.03.2014). (B) Bar graphs representing the volumes of main brain lesions 
that were followed up in the clinics. Note that two small lesions in the basilar ganglion (BM2) were followed up in the clinical care of 
this patient. (C) Heatmap depicting the cancer cell fractions (CCF) of the mutations as defined by ABSOLUTE [11] in the primary breast 
cancer and the metachronous brain metastases. Color key for CCF is depicted. Red and orange dots indicate likely pathogenic mutations and 
mutations affecting cancer genes [12–14], respectively. Asterisk (*) indicate hotspot mutation [17]. The presence of loss of heterozygosity 
is represented by a diagonal bar, and clonal mutations are indicated by an orange box. (D) Genome plots of the primary tumor and the three 
brain metastatic lesions highlighting ERBB2 gene amplification, KRAS amplification and CDKN2A homozygous deletion. Smoothed Log2 
ratios were plotted on the y-axis according to their genomic positions indicated on the x-axis. (E) Phylogenetic tree constructed from the 
somatic mutations, amplifications and homozygous deletions highlighting the main genetic alterations for each sample sequenced. The 
branch lengths are proportional to the number of genetic alterations.
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Figure 2: The repertoire of somatic genetic alterations in primary breast cancers and their respective brain metastases. 
Heatmap depicting the cancer cell fractions (CCF) of the mutations as defined by ABSOLUTE [11] in the primary breast tumors and the 
metachronous brain metastases. CCFs are depicted according to the color key. Red and orange dots indicate likely pathogenic mutations and 
mutations affecting cancer genes [12–14], respectively. Asterisks (*) indicate hotspot mutations [17]. The presence of loss of heterozygosity 
(LOH) of the wild-type allele is represented by a diagonal bar, and mutations considered clonal by ABSOLUTE [11] are indicated by an 
orange box.
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however, we identified potentially actionable genetic 
alterations private to, enriched in or associated with 
secondary LOH events in the brain lesions in ATR, BRAF, 
FGFR2, MAP2K4, PIK3CA, RAF1 and TP53. It should 
be noted that some of the TP53 and PI3KCA mutations 
were private mutations (that is, not found in matched 
primary tumors – TP53: cases 1 and 2; PI3KCA: 
case index). These variants are usually clonal in primary 
breast tumors, although they have also been reported 
to be subclonal in a subset of primary breast cancers 
[41]. In this cohort, these alterations were clonal in the 
brain metastasis of cases index and 1. We cannot exclude 
the possibility that these mutations would have been 
detected in the primary tumors with deeper sequencing or 
as a minor clone in spatially distinct areas of the primary 
tumor. It is unlikely, however, that these alterations 
would not have been detected in the primary tumor if 
they were present in the dominant clone of the primary 
tumor.  In addition, caution should be exercised in the 
interpretation the clinical impact of these somatic genetic 
alterations, given that these databases are evolving. 
For example, TP53 mutations are not considered 
therapeutically actionable by OncoKB [23] but TP53 
was considered an actionable gene by DGIdb [21, 22]. 
Second, we performed a targeted sequencing analysis 
for the 254 genes frequently mutated in breast cancer 
and/or involved in DNA repair. Whole-exome/genome 
sequencing may reveal even more potentially actionable 
or targetable genetic alterations restricted to or enriched 
in the metastatic lesions or primary breast cancers [42]. 
Third, in the expansion cohort, the brain metastases 
were not amenable to punches or biopsies in spatially 
separated areas of the tumors. In clinical practice, 
sampling brain metastases as the sole site of disease or in 
the context of disseminated extra-cranial breast disease 
is practically unfeasible [8, 43, 44]. Cell-free DNA from 
cerebro-spinal fluid [43] may be more appropriate in 
capturing the genetic heterogeneity and private mutations 
within the brain metastases, but unlike the current study, 
we would not have been able to attribute the mutations 
to the brain metastasis. 
Despite these limitations, this study provides 
evidence that genetic alterations that are private to 
or enriched in the brain metastases of HER2-positive 
breast cancers may represent potential targets for 
pharmacological inhibition. We would contend that studies 
of larger patient cohorts and of larger collections of genes 
are warranted to expand the characterization of potentially 
Figure 3: Progression and associated shift in clonal composition of Case 12. (A) Fluorescent in situ hybridization representative 
micrographs characterize the HER2 status of the primary breast cancer, brain metastasis #1, brain metastasis #2 as HER2-amplified. 
HER2/CEP17 ratio and HER2 gene copy number are shown for each sample. Scale bar: 5 microns. (B) Schematic shows shifts in clonal 
composition from the diagnosis of primary breast cancer to the development of two sequential brain metastases over a period of 60.8 
months. Genes affected by likely pathogenic mutations are illustrated. P53 expression has a focal pattern in the primary tumor and is 
enriched in the brain metastasis (more than 80% of the cells) as depicted in the representative micrograph of immunohistochemistry with 
antibodies against p53 (See Materials and Methods, original magnifications 100X).
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targetable genetic alterations in HER2-positive breast 
cancer patients with brain metastasis.
MATERIALS AND METHODS
Patients and samples
An index HER2-positive breast cancer patient with 
multiple anatomically distinct brain metastatic deposits 
and complete clinical remission of the systemic disease 
at the time of death was subjected to a rapid autopsy. 
Five additional HER2-positive breast cancer patients, 
who had minimal or absent extra-cranial disease, were 
subjected to brain metastases excision were also included 
(Table 1, Supplementary Methods). Tumor and matched 
normal tissue were subjected to microdissection and DNA 
extraction as previously reported [43]. 
Immunohistochemistry and fluorescence in situ 
hybridization
HER2 status was assessed in all primary breast 
tumor tissues by either immunohistochemistry (IHC) and/
or fluorescence in situ hybridization (FISH) according to 
the American Society of Clinical Oncologists (ASCO)/
College of American Pathologists (CAP) guidelines 
[45] (Supplementary Methods). p53 IHC was performed 
using the clone DO7 antibody (Cell Marque, Rocklin, 
CA). Tumors were classified as p53-positive if > 10% of 
morphologically unequivocal neoplastic cells displayed 
strong nuclear expression as previously described [46].
Targeted capture massively parallel sequencing
Tumor and matched normal DNA samples were 
subjected to targeted sequencing using a previously 
described customized panel targeting all exons of 
254 genes recurrently mutated in breast cancer and/
or related to DNA repair (Supplementary Table 1 and 
Supplementary Methods) [47, 48]. Bioinformatics 
analyses were performed as previously described [46–
51]. Allele-specific copy number alterations (CNAs) and 
loss of heterozygosity (LOH) of the wild-type allele in 
genes harboring a somatic mutation were inferred using 
FACETS [19]. Sequence reads have been deposited to the 
NCBI Sequence Read Archive (SRP070781). 
Validation of mutations by amplicon sequencing
Selected mutations found by targeted sequencing (n 
= 108, consisting of 104 unique mutations) were subjected 
to orthogonal validation using amplicon resequencing in all 
samples for a given patient, where sufficient genomic DNA 
was available (Supplementary Table 3 and Supplementary 
Methods). The validation rate of the somatic mutations 
with sufficient coverage was 93% (100/108). 
Identification of mutations private to or enriched 
in the brain metastatic lesion
ABSOLUTE (v1.0.6) [11, 52] was used to infer the 
cancer cell fraction (CCF) of mutations and the mutations 
were classified as clonal or subclonal as previously 
described [46–48, 53] (Supplementary Methods). 
Mutations were defined as ‘private to the metastatic 
lesion’ if they were absent in the primary tumor but 
present in the brain metastasis. Mutations were defined as 
‘enriched in the brain metastasis’ if their CCFs increased 
by at least 20% in the brain metastases compared to the 
respective primary tumors. Mutations associated with 
LOH of the wild-type allele in the metastasis but not in 
the corresponding primary tumor were defined as ‘LOH 
in metastasis’.
Identification of potentially pathogenic and/or 
actionable somatic genetic alterations
MutationTaster, CHASM (breast) and FATHMM 
[54–56] were used to define the potential functional effect of 
missense single nucleotide variants as previously described 
[46–48, 53, 57] (Supplementary Methods). Frameshift, 
splice-site and nonsense mutations were considered likely 
pathogenic if they were targeted by loss of the wild-type 
allele or affected haploinsufficient genes [58]. The Drug-
Gene Interaction database (DGIdb) [21, 22] and the 
OncoKB platform [23] were used to investigate the clinical 
actionability of mutated genes (Supplementary Methods). 
Phylogenetic tree construction 
A maximum parsimony tree was built for the index 
case using binary presence/absence matrix based on the 
somatic non-synonymous and synonymous mutations, 
gene amplifications and homozygous deletions in the 
biopsies of the primary tumor and the metastatic lesions, as 
previously described [59, 60] and Supplementary Methods. 
Mutational signatures
Decomposition of the mutational signature was 
performed using deconstructSigs [61], based on the set of 
30 mutational signatures (“signature.cosmic”, based on the 
signatures at http://cancer.sanger.ac.uk/cosmic/signatures 
[15, 20]), for the case with at least 20 somatic mutations. 
Statistical analysis
All statistical analyses were performed in R v3.1.2. 
Comparisons of continuous variables were performed 
using Mann-Whitney U tests. Association was performed 
using the Spearman rank-correlation test. All statistical 
tests were two-tailed and P < 0.05 was considered 
statistically significant.
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